<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Ther Clin Risk Manag</journal-id><journal-id journal-id-type="iso-abbrev">Ther Clin Risk Manag</journal-id><journal-id journal-id-type="publisher-id">Therapeutics and Clinical Risk Management</journal-id><journal-title-group><journal-title>Therapeutics and Clinical Risk Management</journal-title></journal-title-group><issn pub-type="ppub">1176-6336</issn><issn pub-type="epub">1178-203X</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27274259</article-id><article-id pub-id-type="pmc">4869595</article-id><article-id pub-id-type="doi">10.2147/TCRM.S104109</article-id><article-id pub-id-type="publisher-id">tcrm-12-743</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Microplasma radiofrequency technology combined with triamcinolone improved the therapeutic effect on Chinese patients with hypertrophic scar and reduced the risk of tissue atrophy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Shui</given-names></name><xref ref-type="aff" rid="af1-tcrm-12-743"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Hengjin</given-names></name><xref ref-type="aff" rid="af1-tcrm-12-743"/><xref ref-type="corresp" rid="c1-tcrm-12-743"/></contrib></contrib-group><aff id="af1-tcrm-12-743">Department of Dermatology, Chinese People&#x02019;s Liberation Army General Hospital and Hainan Branch, Sanya, People&#x02019;s Republic of China</aff><author-notes><corresp id="c1-tcrm-12-743">Correspondence: Hengjin Li, Department of Dermatology, Chinese People&#x02019;s Liberation Army General Hospital and Hainan Branch, Sanya 572013, People&#x02019;s Republic of China, Tel +86 0898 3733 3030, Email <email>15692537287@163.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>10</day><month>5</month><year>2016</year></pub-date><volume>12</volume><fpage>743</fpage><lpage>747</lpage><permissions><copyright-statement>&#x000a9; 2016 Yu and Li. This work is published and licensed by Dove Medical Press Limited</copyright-statement><copyright-year>2016</copyright-year><license><license-p>The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><sec><title>Objective</title><p>The current study aimed to assess the value of microplasma radiofrequency technology combined with triamcinolone for the therapy of Chinese patients with hypertrophic scar.</p></sec><sec><title>Methods</title><p>A total of 120 participants with hypertrophic scars were enrolled in the current study. Participants were divided into two groups based on sex, and then randomly and evenly divided into four groups (Groups A, B, C, and D). Participants in Group A received microplasma radiofrequency technology combined with triamcinolone. Participants in Group B received microplasma radiofrequency technology combined with normal saline. Participants in Groups C and D received triamcinolone (40 and 10 mg/mL) injected directly into scar. Experienced physicians evaluated the condition of scars according to the Vancouver Scar Scale 1 month before and after the therapy.</p></sec><sec><title>Results</title><p>There was no difference in age, sex, area, height and location of scars, and Vancouver Scar Scale scores before the therapy between any groups (<italic>P</italic>&#x0003e;0.05 for all). Vancouver Scar Scale scores after the therapy were significantly lower than those before the therapy in all groups (<italic>P</italic>&#x0003c;0.05 for all). Vancouver Scar Scale scores after the therapy in Group A were significantly lower than those after the therapy in Groups B and C (<italic>P</italic>&#x0003c;0.05 for all). Vancouver Scar Scale scores after the therapy in Group B were significantly higher than those after the therapy in Group C (<italic>P</italic>&#x0003c;0.05 for all) and similar to those after the therapy in Group D (<italic>P</italic>&#x0003e;0.05 for all). Incidences of tissue atrophy after the therapy were significantly lower in Groups A and B than in Group C (<italic>P</italic>&#x0003c;0.05 for all) and similar among Groups A, B, and D (<italic>P</italic>&#x0003e;0.05 for all).</p></sec><sec><title>Conclusion</title><p>Microplasma radiofrequency technology combined with triamcinolone improved the therapeutic effect on Chinese patients with hypertrophic scar and reduced the risk of tissue atrophy compared with the use of either microplasma radiofrequency technology or triamcinolone injection alone.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>hypertrophic scar</kwd><kwd>microplasma radiofrequency technology</kwd><kwd>tissue atrophy</kwd><kwd>triamcinolone</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Hypertrophic scar is the excessive deposition of extracellular matrix, including collagen, as the result of the wound healing process going out of control and extending beyond the skin surface but limited to the original scope, accompanied by congestion, itch, pain, and other clinical symptoms. Because of the effect of hypertrophic scar on body appearance and impairment of functional activity, dermatologists are in a continued pursuit to seek an effective and safe therapy for hypertrophic scar. Current therapies for hypertrophic scar, such as drug, surgery, isotope, laser, pressure, and cryotherapy, not only have limited efficacy but also lead to secondary damage including tissue atrophy.<xref rid="b1-tcrm-12-743" ref-type="bibr">1</xref>&#x02013;<xref rid="b4-tcrm-12-743" ref-type="bibr">4</xref> The most widely used glucocorticoid injection is difficult to operate, and injecting glucocorticoids unevenly or into normal tissue often results in tissue atrophy and other adverse reactions.<xref rid="b5-tcrm-12-743" ref-type="bibr">5</xref>,<xref rid="b6-tcrm-12-743" ref-type="bibr">6</xref> So, it is necessary to explore a new method to import glucocorticoids into scar tissue. Microplasma radiofrequency technology, a recently presented therapy for hypertrophic scars, can stimulate the plasma and form microchannels in the corium layer.<xref rid="b7-tcrm-12-743" ref-type="bibr">7</xref>&#x02013;<xref rid="b9-tcrm-12-743" ref-type="bibr">9</xref> Triamcinolone is a long-acting glucocorticoid with good efficacy in eliminating hypertrophic scar, and it can be imported into the scar tissue through microplasma radiofrequency technology.<xref rid="b1-tcrm-12-743" ref-type="bibr">1</xref> Comprehensive therapy combining two or more kinds of conventional therapies has received more and more attention in recent years because of its better therapy efficacy and lower rates of adverse reactions. There are very few studies on the combined use of microplasma radiofrequency technology and triamcinolone in the therapy of hypertrophic scar all over the world, especially in the People&#x02019;s Republic of China. The current study aimed to assess the value of microplasma radiofrequency technology combined with triamcinolone for the therapy of hypertrophic scar.</p></sec><sec sec-type="methods"><title>Methods</title><sec sec-type="methods|subjects"><title>Study participants</title><p>A total of 120 Chinese participants with hypertrophic scars were enrolled in the current study. They were aged older than 18 years, and half of them were male and the other half were female. They had no basic diseases or contraindications to glucocorticoids. All their hypertrophic scars were present for &#x0003e;1 year without significantly fading for &#x0003e;6 months and were higher than the skin surface and were associated with the symptoms of congestion, itch, and pain. These hypertrophic scars were located in head and face, chest and back, and limbs, respectively. Participants were divided into two groups based on sex, and then randomly and evenly divided into four groups (Groups A, B, C, and D). Participants in Group A received microplasma radiofrequency technology combined with triamcinolone (40 mg/mL). Participants in Group B received microplasma radiofrequency technology combined with normal saline. Participants in Group C received triamcinolone (40 mg/mL) injected directly and slowly into the scar.<xref rid="b8-tcrm-12-743" ref-type="bibr">8</xref> Participants in Group D received triamcinolone (10 mg/mL) injected directly and slowly into the scar.<xref rid="b10-tcrm-12-743" ref-type="bibr">10</xref> A course of therapy included the standard therapy administered five times with an interval of 1 month between each administration for all groups. The study protocol was approved by the Ethics Committee of Chinese People&#x02019;s Liberation Army General Hospital and performed according to the Declaration of Helsinki. Each participant provided written informed consent to be included in the study.</p></sec><sec><title>Microplasma radiofrequency technology</title><p>A plasma beam scar therapy apparatus (Accent XL; Alma Lasers Ltd., Caesarea, Israel) with a roller head was used. The roller head was rolled on the skin from different directions five times to form microchannels in the scar tissue. The apparatus was used at 60&#x02013;70 W and 4&#x02013;6 mA.<xref rid="b7-tcrm-12-743" ref-type="bibr">7</xref> Triamcinolone (Group A) or normal saline (Group B) was smeared on the rolling region and imported into scar tissue by microplasma radiofrequency technology.</p></sec><sec><title>Vancouver Scar Scale</title><p>Experienced physicians evaluated the condition of scars according to the Vancouver Scar Scale 1 month before and after the therapy. Vancouver Scar Scale is a 15-point scoring system scored as follows: color (0, similar to the rest of skin; 1, shallower than the rest of skin; 2, mixed color; 3, deeper than the rest of skin), vascular distribution (0, similar to the rest of skin; 1, pink; 2, red; 3, purple), thickness (0, normal; 1, &#x0003e;0&#x02013;1 mm; 2, &#x0003e;1&#x02013;2 mm; 3, &#x0003e;2&#x02013;3 mm; 4, &#x0003e;4 mm), and flexibility (0, normal; 1, soft [with deformation under the least pressure]; 2, supple [with deformation under pressure]; 3, hard [with resistance to pressure and without deformation]; 4, bending [with retraction during stretching like a rope]; 5, contracture [with permanent shortening leading to distortion and disability]). They were summed for a total Vancouver Scar Scale score ranging from 0 to 15, and a higher score indicated a heavier scar.<xref rid="b11-tcrm-12-743" ref-type="bibr">11</xref> Participants were asked not to tell the dermatologists their grouping situation.</p></sec><sec sec-type="methods"><title>Statistical analysis</title><p>Continuous variables were presented as mean (standard deviation) or median (interquartile range). Categorical variables were presented as number (percentage). Continuous variables were compared using Student&#x02019;s <italic>t</italic>-test or Mann&#x02013;Whitney <italic>U</italic>-test. Categorical variables were compared using chi-square test. A <italic>P</italic>-value &#x0003c;0.05 was deemed as statistically significant. Statistical analysis was performed using SPSS 17.0 (SPSS Inc., Chicago, IL, USA).</p></sec></sec><sec sec-type="results"><title>Results</title><p>Participant features and Vancouver Scar Scale scores before and after the therapy are shown in <xref ref-type="table" rid="t1-tcrm-12-743">Table 1</xref>. There was no difference in age, sex, area, height and location of scars, and Vancouver Scar Scale scores before the therapy between any groups (<italic>P</italic>&#x0003e;0.05 for all). Vancouver Scar Scale scores after the therapy were significantly lower than those before the therapy in all groups (<italic>P</italic>&#x0003c;0.05 for all). Vancouver Scar Scale scores after the therapy in Group A were significantly lower than those after the therapy in Groups B, C, and D (<italic>P</italic>&#x0003c;0.05 for all). Vancouver Scar Scale scores after the therapy in Group B were significantly higher than those after the therapy in Group C (<italic>P</italic>&#x0003c;0.05 for all). Vancouver Scar Scale scores after the therapy in Group B were similar to those after the therapy in Group D (<italic>P</italic>&#x0003e;0.05 for all). Incidences of tissue atrophy after the therapy were significantly lower in Groups A and B than in Group C (<italic>P</italic>&#x0003c;0.05 for all). Incidences of tissue atrophy after the therapy were similar among Groups A, B, and D (<italic>P</italic>&#x0003e;0.05 for all).</p></sec><sec sec-type="discussion"><title>Discussion</title><p>Lately, microplasma radiofrequency technology has become commercially available and clinically acceptable as novel fractional lasers in dermatology.<xref rid="b7-tcrm-12-743" ref-type="bibr">7</xref> Its roller head has several rows of equidistantly and closely arrayed needles, leaving a thin layer of air space above the skin surface. Plasma is similar to the gaseous state, including some ionized molecules, and very sensitive to electromagnetic fields, and radiofrequency wave stimulates the spark plasma between the needles and skin surface. Various effects can be achieved, from vaporization to heating of scar tissue, through the interaction between spark plasma and scar tissue. Spark plasma mildly peels the cuticular layer and forms the microchannel in corium layer. The depth and diameter of microchannel depend on the energy of radiofrequency and duration of pulse, and these are generally 100&#x02013;150 and 80&#x02013;120 &#x003bc;m, respectively. The multipoint radiofrequency technology improves the traditional radiofrequency technology, which only produces high-energy flake discharge, and increases the temperature in each tiny focus with stimulating spark plasma.<xref rid="b8-tcrm-12-743" ref-type="bibr">8</xref></p><p>Scar is a natural part of dermal healing process and consists of a network of fibrous collagen tissue laid down in response to injury to the dermis. In some genetically susceptible individuals, the process of scar tissue formation is excessive, and there is an oversecretion of collagen.<xref rid="b2-tcrm-12-743" ref-type="bibr">2</xref> The use of glucocorticoids injection is, to date, the core therapy available for the management of excessive tissue production in scar. As the most effective regimen for management of hypertrophic scar, the therapeutic value of triamcinolone on hypertrophic scar has been reported in the literature.<xref rid="b1-tcrm-12-743" ref-type="bibr">1</xref> Triamcinolone inhibits the expression of vascular endothelial growth factor to restrain the fibroblast proliferation, increases the collagen breakdown, and promotes the scar tissue degradation.<xref rid="b12-tcrm-12-743" ref-type="bibr">12</xref> However, the most commonly applied triamcinolone injection is difficult to operate, and injecting triamcinolone unevenly or into normal tissue often leads to adverse reactions including tissue atrophy and poor management of hyperplastic scar.<xref rid="b5-tcrm-12-743" ref-type="bibr">5</xref>,<xref rid="b6-tcrm-12-743" ref-type="bibr">6</xref> Microplasma radiofrequency technology and its thermal effect stimulate fibroblasts to synthesize the new collagen fibers and matrixes in scar tissue on the one hand and rearrange the disordered collagen fibers to make scar tissue closer to normal skin on the other hand.<xref rid="b9-tcrm-12-743" ref-type="bibr">9</xref> Moreover, microplasma radiofrequency technology stimulates the plasma and forms the microchannel in corium layer, and triamcinolone can be absorbed effectively and evenly by scar tissue through microplasma radiofrequency technology.<xref rid="b1-tcrm-12-743" ref-type="bibr">1</xref> The combined use of microplasma radiofrequency technology and triamcinolone can achieve good therapeutic effect for hypertrophic scar and help avoid obvious adverse reactions including tissue atrophy. The current study applied the objective and effective Vancouver Scar Scale as evaluation standard for hypertrophic scar and provided evidence for the therapeutic effect and safety of microplasma radiofrequency technology combined with triamcinolone on improvement of Chinese patients with hypertrophic scar superior to use of either microplasma radiofrequency technology or triamcinolone alone.</p></sec><sec><title>Conclusion</title><p>Collectively, the current study demonstrated that microplasma radiofrequency technology combined with triamcinolone improved the therapeutic effect on Chinese patients with hypertrophic scar and reduced the risk of tissue atrophy compared with use of either microplasma radiofrequency technology or triamcinolone injection alone.</p></sec></body><back><fn-group><fn><p><bold>Disclosure</bold></p><p>The authors report no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-tcrm-12-743"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berman</surname><given-names>B</given-names></name><name><surname>Flores</surname><given-names>F</given-names></name></person-group><article-title>The therapy of hypertrophic scars and keloids</article-title><source>Eur J Dermatol</source><year>1998</year><volume>8</volume><issue>8</issue><fpage>591</fpage><lpage>595</lpage><pub-id pub-id-type="pmid">9889433</pub-id></element-citation></ref><ref id="b2-tcrm-12-743"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jalali</surname><given-names>M</given-names></name><name><surname>Bayat</surname><given-names>A</given-names></name></person-group><article-title>Current use of steroids in management of abnormal raised skin scars</article-title><source>Surgeon</source><year>2007</year><volume>5</volume><issue>3</issue><fpage>175</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">17575671</pub-id></element-citation></ref><ref id="b3-tcrm-12-743"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waibel</surname><given-names>J</given-names></name><name><surname>Beer</surname><given-names>K</given-names></name></person-group><article-title>Ablative fractional laser resurfacing for the treatment of a third-degree burn</article-title><source>J Drugs Dermatol</source><year>2009</year><volume>8</volume><issue>3</issue><fpage>294</fpage><lpage>297</lpage><pub-id pub-id-type="pmid">19271380</pub-id></element-citation></ref><ref id="b4-tcrm-12-743"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sklar</surname><given-names>LR</given-names></name><name><surname>Burnett</surname><given-names>CT</given-names></name><name><surname>Waibel</surname><given-names>JS</given-names></name><name><surname>Moy</surname><given-names>RL</given-names></name><name><surname>Ozog</surname><given-names>DM</given-names></name></person-group><article-title>Laser assisted drug delivery: a review of an evolving technology</article-title><source>Lasers Surg Med</source><year>2014</year><volume>46</volume><issue>4</issue><fpage>249</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">24664987</pub-id></element-citation></ref><ref id="b5-tcrm-12-743"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>AP</given-names></name></person-group><article-title>Medical and surgical therapies for keloids</article-title><source>Dermatol Ther</source><year>2004</year><volume>17</volume><issue>2</issue><fpage>212</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">15113289</pub-id></element-citation></ref><ref id="b6-tcrm-12-743"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mutalink</surname><given-names>S</given-names></name></person-group><article-title>The therapy of keloids and hypertrophic scars</article-title><source>Indian J Dermatol Venereol</source><year>2005</year><volume>71</volume><issue>1</issue><fpage>3</fpage><lpage>8</lpage></element-citation></ref><ref id="b7-tcrm-12-743"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xin</surname><given-names>F</given-names></name><name><surname>Li-hong</surname><given-names>L</given-names></name><name><surname>Alexiades-Armenakas</surname><given-names>M</given-names></name><etal/></person-group><article-title>Histological and electron microscopic analysis of fractional micro-plasma radio-frequency technology effects</article-title><source>J Drugs Dermatol</source><year>2013</year><volume>12</volume><issue>11</issue><fpage>1210</fpage><lpage>1214</lpage><pub-id pub-id-type="pmid">24196327</pub-id></element-citation></ref><ref id="b8-tcrm-12-743"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halachmi</surname><given-names>S</given-names></name><name><surname>Orenstein</surname><given-names>A</given-names></name><name><surname>Meneghel</surname><given-names>T</given-names></name><name><surname>Lapidoth</surname><given-names>M</given-names></name></person-group><article-title>A novel fractional micro-plasma radio-frequency technology for the therapy of facial scars and rhytids: a pilot study</article-title><source>J Cosmet Laser Ther</source><year>2010</year><volume>12</volume><issue>5</issue><fpage>208</fpage><lpage>212</lpage><pub-id pub-id-type="pmid">20825258</pub-id></element-citation></ref><ref id="b9-tcrm-12-743"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname><given-names>KW</given-names></name><name><surname>Moy</surname><given-names>RL</given-names></name><name><surname>Fincher</surname><given-names>EF</given-names></name></person-group><article-title>Advances in plasma skin regeneration</article-title><source>J Cosmet Dermatol</source><year>2008</year><volume>7</volume><issue>3</issue><fpage>169</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">18789051</pub-id></element-citation></ref><ref id="b10-tcrm-12-743"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carvalhaes</surname><given-names>SM</given-names></name><name><surname>Petroianu</surname><given-names>A</given-names></name><name><surname>Ferreira</surname><given-names>MA</given-names></name><name><surname>de Barros</surname><given-names>VM</given-names></name><name><surname>Lopes</surname><given-names>RV</given-names></name></person-group><article-title>Assessment of the treatment of earlobe keloids with triamcinolone injections, surgical resection, and local pressure</article-title><source>Rev Col Bras Cir</source><year>2015</year><volume>42</volume><issue>1</issue><fpage>9</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">25992694</pub-id></element-citation></ref><ref id="b11-tcrm-12-743"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sood</surname><given-names>RF</given-names></name><name><surname>Hocking</surname><given-names>AM</given-names></name><name><surname>Muffley</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Genome-wide association study of postburn scarring identifies a novel protective variant</article-title><source>Ann Surg</source><year>2015</year><volume>262</volume><issue>4</issue><fpage>563</fpage><lpage>569</lpage><pub-id pub-id-type="pmid">26366535</pub-id></element-citation></ref><ref id="b12-tcrm-12-743"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>SB</given-names></name><name><surname>Russell</surname><given-names>JD</given-names></name><name><surname>Trupin</surname><given-names>JS</given-names></name></person-group><article-title>Hydrocortisone induction of system A amino acid transport in human fibroblasts from normal dermis and keloid</article-title><source>J Biol Chem</source><year>1984</year><volume>259</volume><fpage>11464</fpage><lpage>11469</lpage><pub-id pub-id-type="pmid">6470008</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="t1-tcrm-12-743" position="float"><label>Table 1</label><caption><p>Participant features and Vancouver Scar Scale scores before and after the therapy</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Features</th><th valign="top" align="left" rowspan="1" colspan="1">Group A</th><th valign="top" align="left" rowspan="1" colspan="1">Group B</th><th valign="top" align="left" rowspan="1" colspan="1">Group C</th><th valign="top" align="left" rowspan="1" colspan="1">Group D</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value<xref ref-type="table-fn" rid="tfn1-tcrm-12-743">a</xref></th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value<xref ref-type="table-fn" rid="tfn2-tcrm-12-743">b</xref></th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value<xref ref-type="table-fn" rid="tfn3-tcrm-12-743">c</xref></th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value<xref ref-type="table-fn" rid="tfn4-tcrm-12-743">d</xref></th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value<xref ref-type="table-fn" rid="tfn5-tcrm-12-743">e</xref></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years), mean (standard deviation)</td><td valign="top" align="left" rowspan="1" colspan="1">27 (6.7)</td><td valign="top" align="left" rowspan="1" colspan="1">28 (6.4)</td><td valign="top" align="left" rowspan="1" colspan="1">28 (6.6)</td><td valign="top" align="left" rowspan="1" colspan="1">27 (6.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.875</td><td valign="top" align="left" rowspan="1" colspan="1">0.892</td><td valign="top" align="left" rowspan="1" colspan="1">0.984</td><td valign="top" align="left" rowspan="1" colspan="1">0.862</td><td valign="top" align="left" rowspan="1" colspan="1">0.738</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Men, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">15 (50)</td><td valign="top" align="left" rowspan="1" colspan="1">15 (50)</td><td valign="top" align="left" rowspan="1" colspan="1">15 (50)</td><td valign="top" align="left" rowspan="1" colspan="1">15 (50)</td><td valign="top" align="left" rowspan="1" colspan="1">1.000</td><td valign="top" align="left" rowspan="1" colspan="1">1.000</td><td valign="top" align="left" rowspan="1" colspan="1">1.000</td><td valign="top" align="left" rowspan="1" colspan="1">1.000</td><td valign="top" align="left" rowspan="1" colspan="1">1.000</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Area (cm<sup>2</sup>), median (interquartile range)</td><td valign="top" align="left" rowspan="1" colspan="1">5.5 (2.0&#x02013;9.0)</td><td valign="top" align="left" rowspan="1" colspan="1">4.5 (1.0&#x02013;9.0)</td><td valign="top" align="left" rowspan="1" colspan="1">4.0 (1.0&#x02013;8.0)</td><td valign="top" align="left" rowspan="1" colspan="1">5.5 (2.0&#x02013;9.0)</td><td valign="top" align="left" rowspan="1" colspan="1">0.570</td><td valign="top" align="left" rowspan="1" colspan="1">0.310</td><td valign="top" align="left" rowspan="1" colspan="1">0.730</td><td valign="top" align="left" rowspan="1" colspan="1">0.917</td><td valign="top" align="left" rowspan="1" colspan="1">0.633</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Height (cm), median (interquartile range)</td><td valign="top" align="left" rowspan="1" colspan="1">0.35 (0.20&#x02013;0.40)</td><td valign="top" align="left" rowspan="1" colspan="1">0.30 (0.20&#x02013;0.40)</td><td valign="top" align="left" rowspan="1" colspan="1">0.30 (0.20&#x02013;0.40)</td><td valign="top" align="left" rowspan="1" colspan="1">0.30 (0.20&#x02013;0.40)</td><td valign="top" align="left" rowspan="1" colspan="1">0.508</td><td valign="top" align="left" rowspan="1" colspan="1">0.358</td><td valign="top" align="left" rowspan="1" colspan="1">0.748</td><td valign="top" align="left" rowspan="1" colspan="1">0.525</td><td valign="top" align="left" rowspan="1" colspan="1">0.950</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Location, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Head and face</td><td valign="top" align="left" rowspan="1" colspan="1">11 (36.7)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (23.3)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (26.7)</td><td valign="top" align="left" rowspan="1" colspan="1">13 (43.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.505</td><td valign="top" align="left" rowspan="1" colspan="1">0.534</td><td valign="top" align="left" rowspan="1" colspan="1">0.858</td><td valign="top" align="left" rowspan="1" colspan="1">0.812</td><td valign="top" align="left" rowspan="1" colspan="1">0.206</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Chest and back</td><td valign="top" align="left" rowspan="1" colspan="1">10 (33.3)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (36.7)</td><td valign="top" align="left" rowspan="1" colspan="1">9 (30)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (33.3)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Limbs</td><td valign="top" align="left" rowspan="1" colspan="1">9 (30)</td><td valign="top" align="left" rowspan="1" colspan="1">12 (40)</td><td valign="top" align="left" rowspan="1" colspan="1">13 (43.3)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (23.3)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Vancouver Scar Scale score before the therapy (%)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;6</td><td valign="top" align="left" rowspan="1" colspan="1">5 (16.7)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (26.7)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (33.3)</td><td valign="top" align="left" rowspan="1" colspan="1">6 (20.0)</td><td valign="top" align="left" rowspan="1" colspan="1">0.547</td><td valign="top" align="left" rowspan="1" colspan="1">0.416</td><td valign="top" align="left" rowspan="1" colspan="1">0.925</td><td valign="top" align="left" rowspan="1" colspan="1">0.880</td><td valign="top" align="left" rowspan="1" colspan="1">0.458</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;7</td><td valign="top" align="left" rowspan="1" colspan="1">12 (40.0)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (33.3)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (33.3)</td><td valign="top" align="left" rowspan="1" colspan="1">14 (46.7)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;8</td><td valign="top" align="left" rowspan="1" colspan="1">7 (23.3)</td><td valign="top" align="left" rowspan="1" colspan="1">9 (30.0)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (23.3)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (16.7)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;9</td><td valign="top" align="left" rowspan="1" colspan="1">6 (20.0)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (10.0)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (10.0)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (16.7)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Vancouver Scar Scale score after the therapy (%)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;3</td><td valign="top" align="left" rowspan="1" colspan="1">6 (20.0)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (10.0)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3)</td><td valign="top" align="left" rowspan="1" colspan="1">,0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.039</td><td valign="top" align="left" rowspan="1" colspan="1">0.002</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.557</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;4</td><td valign="top" align="left" rowspan="1" colspan="1">18 (60.0)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (6.7)</td><td valign="top" align="left" rowspan="1" colspan="1">9 (30.0)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (16.7)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;5</td><td valign="top" align="left" rowspan="1" colspan="1">4 (13.3)</td><td valign="top" align="left" rowspan="1" colspan="1">6 (20.0)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (36.7)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (23.3)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;6</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3)</td><td valign="top" align="left" rowspan="1" colspan="1">13 (43.3)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (13.3)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (33.3)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;7</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3)</td><td valign="top" align="left" rowspan="1" colspan="1">9 (30.0)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (10.0)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (23.3)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value<xref ref-type="table-fn" rid="tfn6-tcrm-12-743">f</xref></td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.001</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Tissue atrophy, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="left" rowspan="1" colspan="1">6 (20.0)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (13.3)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.031</td><td valign="top" align="left" rowspan="1" colspan="1">0.031</td><td valign="top" align="left" rowspan="1" colspan="1">0.121</td><td valign="top" align="left" rowspan="1" colspan="1">0.121</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn1-tcrm-12-743"><label>a</label><p><italic>P</italic>-value was drawn from comparisons between Groups A and B;</p></fn><fn id="tfn2-tcrm-12-743"><label>b</label><p><italic>P</italic>-value was drawn from comparisons between Groups A and C;</p></fn><fn id="tfn3-tcrm-12-743"><label>c</label><p><italic>P</italic>-value was drawn from comparisons between Groups B and C;</p></fn><fn id="tfn4-tcrm-12-743"><label>d</label><p><italic>P</italic>-value was drawn from comparisons between Groups A and D;</p></fn><fn id="tfn5-tcrm-12-743"><label>e</label><p><italic>P</italic>-value was drawn from comparisons between Groups B and D;</p></fn><fn id="tfn6-tcrm-12-743"><label>f</label><p><italic>P</italic>-value was drawn from comparisons of Vancouver Scar Scales before and after the therapy.</p></fn></table-wrap-foot></table-wrap></floats-group></article>